opipramol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
substances of the imipramine group	1993	315-72-0

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

opipramol dihydrochloride
opipramol
opramidol

A tricyclic antidepressant with actions similar to AMITRIPTYLINE.

Molecular weight: 363.51
Formula: C23H29N3O
CLOGP: 3.65
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 29.95
ALOGS: -3.54
ROTB: 6

Drug dosage:

Dose	Unit	Route
0.15	g	O

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	94 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1	53
kinase-selectivity-class	AXL,BRAF,CAMK2D,CDK4,EPHB4,PDK4,SIK2,SIK3,STK33	9
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
General physical health deterioration	183.84	35.27	117	2417	354998	90270915
Product prescribing error	74.61	35.27	29	2505	30116	90595797
Product monitoring error	61.55	35.27	16	2518	4528	90621385
Labelled drug-drug interaction medication error	43.17	35.27	16	2518	14566	90611347
Patient uncooperative	40.49	35.27	7	2527	277	90625636
Fall	39.07	35.27	57	2477	481753	90144160
Skin irritation	36.90	35.27	14	2520	13589	90612324
Pneumobilia	36.82	35.27	6	2528	165	90625748

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Transposition of the great vessels	45.74	38.59	8	884	457	42619986
VACTERL syndrome	44.95	38.59	6	886	53	42620390
Hypoparathyroidism secondary	44.85	38.59	7	885	197	42620246
Visual evoked potentials abnormal	43.84	38.59	6	886	65	42620378
CADASIL	41.50	38.59	6	886	99	42620344
Magnetic resonance imaging spinal abnormal	39.52	38.59	6	886	140	42620303
Hemivertebra	39.48	38.59	6	886	141	42620302
Saccadic eye movement	38.71	38.59	6	886	161	42620282

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
General physical health deterioration	191.23	31.05	128	2939	425167	110161065
Product prescribing error	78.68	31.05	35	3032	51296	110534936
Product monitoring error	50.99	31.05	16	3051	8911	110577321
Hypoparathyroidism secondary	40.42	31.05	7	3060	282	110585950
Fall	34.95	31.05	61	3006	603421	109982811
Pneumobilia	32.93	31.05	6	3061	324	110585908
Patient uncooperative	32.04	31.05	7	3060	953	110585279
Tachycardia	31.52	31.05	35	3032	226610	110359622
Skin irritation	31.13	31.05	13	3054	16306	110569926

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06AA05	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Non-selective monoamine reuptake inhibitors
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D000929	Antidepressive Agents, Tricyclic
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D018759	Adrenergic Uptake Inhibitors
MeSH PA	D049990	Membrane Transport Modulators

Related Drugs by ATC class:

N06AA Non-selective monoamine reuptake inhibitors 20 drugs

amineptine amitriptyline amoxapine butriptyline clomipramine desipramine dibenzepin dimetacrine dosulepin doxepin imipramine imipramine oxide show all 20 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Depressive disorder	indication	35489007

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.21	Basic
pKa2	5.43	Basic
pKa3	4.21	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	9.70		CHEMBL
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Enzyme	Q15125	EBP_HUMAN		Ki	7.89		CHEMBL
Voltage-dependent N-type calcium channel subunit alpha-1B	Ion channel	Q00975	CAC1B_HUMAN		IC50	4.62		CHEMBL
C-8 sterol isomerase	Enzyme		ERG2_YEAST		Ki	7.77		CHEMBL

External reference:

ID	Source
N0000167254	NUI
D08297	KEGG_DRUG
C0029105	UMLSCUI
CHEBI:94614	CHEBI
CHEMBL370753	ChEMBL_ID
CHEMBL1524185	ChEMBL_ID
DB12930	DRUGBANK_ID
D009888	MESH_DESCRIPTOR_UI
9417	PUBCHEM_CID
11247	IUPHAR_LIGAND_ID
1838	INN_ID
D23ZXO613C	UNII
7674	RXNORM
004149	NDDF
004150	NDDF
1156223004	SNOMEDCT_US
1172808004	SNOMEDCT_US
1172810002	SNOMEDCT_US
D23ZXO613C	INXIGHT DRUGS

Pharmaceutical products:

None